UK markets open in 5 hours 53 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
70.41-0.78 (-1.10%)
At close: 4:00PM EDT
70.40 -0.01 (-0.01%)
After hours: 07:59PM EDT

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
http://www.gilead.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees13,600

Key executives

NameTitlePayExercisedYear born
Mr. Daniel P. O'DayChairman & CEO7.48MN/A1964
Mr. Andrew D. DickinsonExec. VP & CFO2.71MN/A1970
Mr. Brett A. PletcherExec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.2.71M1.06M1968
Ms. Johanna MercierChief Commercial Officer4.86MN/A1970
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer3.85MN/A1963
Ms. Diane E. WilfongSr. VP, Corp. Controller & Chief Accounting OfficerN/AN/A1962
Ms. Jacquie Ross C.F.A.VP of Investor RelationsN/AN/AN/A
Ms. Jyoti K. MehraExec. VP of HRN/AN/AN/A
Dr. Taiyin YangExec. VP of Pharmaceutical Devel. & ManufacturingN/AN/A1954
Dr. Diana M. Brainard M.D.Sr. VP of HIV & Emerging Viral InfectionsN/AN/A1971
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Corporate governance

Gilead Sciences, Inc.’s ISS governance QualityScore as of 26 September 2021 is 1. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 2; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.